Medartis Holding AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDRSF research report →
Price Chart
About the company
Medartis Holding AG is a global medical technology firm that develops, manufactures, and distributes implantable solutions. These advanced medical devices are utilized worldwide for the surgical stabilization of bone fractures in both the upper and lower extremities, in addition to addressing complex cranio-maxillofacial surgical needs. The company's portfolio features osteosynthesis instruments, marketed under the APTUS and MODUS brands, specifically designed for various body regions including the hand, wrist, elbow, shoulder, foot, and ankle, as well as for facial and skull procedures involving the mandible, midface, orthognathic structures, and cranium.
- CEO
- Matthias Schupp
- IPO
- 2020
- Employees
- 1,337
- HQ
- Basel, BS, CH
Get TickerSpark's AI analysis on MDRSF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.43B
- P/E
- 95.67
- Fwd P/E
- 77.68
- PEG
- 0.03
- P/S
- 4.65
- P/B
- 5.07
- EV/EBITDA
- 47.55
- Div Yield
- 0.00%
- Gross Margin
- 77.48%
- Op Margin
- 1.61%
- Net Margin
- 4.86%
- ROE
- 5.35%
- ROIC
- 0.61%
Latest fiscal year · YoY change
- Revenue
- $269.26M+19.8%
- Gross Profit
- $204.33M+14.4%
- Op Income
- $1.93M
- Net Income
- $8.35M+136.6%
- EPS
- $0.67+157.7%
- OCF Growth
- +8.6%
- FCF Growth
- -55.5%
- 52W High
- $115.00
- 52W Low
- $100.00
- 50D MA
- $115.00
- 200D MA
- $113.95
- Beta
- 1.17
- RSI (14)
- 100
- Avg Volume
- 121
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Medartis delivered strong first-half organic growth and margin expansion, and raised full-year sales guidance after better-than-expected U.S. TOUCH traction and continued share gains in core markets.· August 18, 2026
- Organic sales grew 17% in H1 2026, while reported group revenue reached CHF 160.8 million, up 30.7% including acquisitions.
- Core EBITDA margin improved to 18%, with core EBITDA of CHF 28.8 million and core gross margin at 81.5%.
- Management raised full-year 2026 core sales guidance to 17% to 19%, citing stronger U.S. momentum and a higher TOUCH case outlook.
- U.S. growth accelerated to 27.4%, helped by TOUCH, while EMEA grew strongly and Latin America was highlighted as a transformation year.
- Cash flow was negative in H1 due to heavy investment, but management expects free cash flow to improve meaningfully in 2027 and 2028.
Medartis reported CHF 160.8 million in group revenue for H1 2026, up 30.7% year over year, including CHF 24.3 million of contributions from NeoOrtho and Keri Medical. Core sales were about CHF 160 million, up CHF 38 million in Swiss francs, with organic growth of 17%. Core gross margin was 81.5%, and core EBITDA was CHF 28.8 million, implying an 18% EBITDA margin. Core net profit increased to almost CHF 7 million, versus a net loss of CHF 400,000 last year. Free cash flow was negative CHF 10 million, reflecting almost CHF 18 million of CapEx; cash balance ended at CHF 26 million. For 2026, management raised full-year core sales guidance to 17% to 19% and said core EBITDA margin should remain in the high teens. TOUCH U.S. units were raised from 1,200 to 1,800 for the year, and management expects around CHF 3 million of additional top-line contribution from that increase.
Matthias Schupp framed the quarter as evidence that Medartis is “delivering on promises,” emphasizing both top-line growth and profitability. He said the company is executing on its strategic priorities: accelerating the U.S., integrating Keri Medical into a “one team” model, expanding Value and NeoOrtho in Latin America, and building a longer-term innovation and digitalization pipeline. His tone was upbeat and confident, repeatedly pointing to culture, execution, and customer centricity as the drivers behind the results.
Peter Hackel walked through the numbers in detail, highlighting core sales of about CHF 160 million, organic growth of 17%, and a CHF 4 million FX headwind on sales. He said core gross margin improved 140 basis points on a constant-currency basis, aided by mix, plant efficiencies, and Keri consolidation, while U.S. tariffs reduced gross margin by 60 basis points; the company received CHF 4.4 million of tariff refunds, of which CHF 800,000 was recognized in core results. He also noted core EBITDA of CHF 28.8 million, net profit of roughly CHF 7 million, CapEx of almost CHF 18 million in H1, a negative free cash flow of CHF 10 million, and an ending cash balance of CHF 26 million. Looking ahead, he expects full-year CapEx to be about CHF 35 million and free cash flow to improve significantly in 2027 and 2028.
Analysts pressed management on the U.S. outlook, asking how much of the guidance raise came from TOUCH versus the underlying base business, whether Titan Nail would create a headwind, and when Keri cross-selling would show up. Management said the higher TOUCH target is part of the story, but not the only reason; the base U.S. business is also improving, with Florida recovery helping second-half comparisons. On Titan Nail, management said the transition from NX Nail should be roughly neutral, because the company is phasing it in alongside existing distribution and does not expect an impact. On cross-selling, management said it is still early, but around 20 surgeons are already using Medartis products they had not used before through TOUCH onboarding. Analysts also asked about TOUCH conversion rates, Europe growth, cash flow, and APAC/Japan; management said many trained surgeons are waiting on hospital contracts, UK strike impacts were slight, free cash flow should improve in later years, and Japan is being revamped with a new general manager.
The positive case from this call is that Medartis is showing broad-based execution: organic growth is still 17%, U.S. growth is accelerating, and TOUCH is scaling faster than initially planned. Management also sounded confident that Europe still has room to run, Latin America is being restructured for future Value and NeoOrtho growth, and the company’s gross margin and EBITDA margin are improving despite tariff and investment pressure.
The main risks discussed were execution and timing: U.S. TOUCH still depends on hospital contracts and surgeon conversion, Florida recovery is not complete, and August is seasonally softer because elective surgery slows. Management also acknowledged that Latin America is in a transformation year, Japan is only now being revamped, and free cash flow remains negative because of heavy CapEx, tariff complexity, and production expansions that will take time to pay off.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 32.6%
- Shares Outstanding
- 12.45M
- Float Shares
- 4.06M
Our MDRSF coverage
Recent articles, reports, and earnings notes.
No research on MDRSF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MDRSF report →Medartis Holding AG (MDRSF) Q2 2026 Press Conference Call Transcript
seekingalpha.com · Aug 18
Medartis Holding AG (MDRSF) Discusses Strategy Roadmap and Innovation in Upper Extremities and Hand Products Transcript
seekingalpha.com · Jun 4
Medartis Holding AG (OTCMKTS:MDRSF) Short Interest Down 12.8% in February
defenseworld.net · Mar 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.